Barclays analyst Matt Miksic maintains $Tandem Diabetes Care (TNDM.US)$ with a buy rating, and adjusts the target price from $58 to $60.
According to TipRanks data, the analyst has a success rate of 62.0% and a total average return of 7.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Tandem Diabetes Care (TNDM.US)$'s main analysts recently are as follows:
Tandem Diabetes has reported another strong growth quarter, prompting an increase in its full-year growth guidance to 17%-18%. This performance is primarily attributed to the ongoing success of the Mobi launch.
In spite of delivering yet another quarter of surpassing expectations and elevating future guidance, the third in a series, shares experienced a downturn. The cause of this market reaction is attributed to the persistent uncertainty regarding the strength of future growth drivers. The perception is that the company has made a decisive positive shift, with the anticipation that foundational aspects will progressively enhance. Nevertheless, a cautious stance is being maintained pending greater assurance in the enduring factors that will propel sales growth.
Analysts noted that Tandem Diabetes' Q3 revenue surpassed expectations, although partial contributions came from timing benefits related to U.S. supplies and international distributor orders. They observed that Q3 pump shipments in the U.S. aligned closely with their projections.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克莱银行分析师Matt Miksic维持$Tandem Diabetes Care (TNDM.US)$买入评级，并将目标价从58美元上调至60美元。
根据TipRanks数据显示，该分析师近一年总胜率为62.0%，总平均回报率为7.5%。
此外，综合报道，$Tandem Diabetes Care (TNDM.US)$近期主要分析师观点如下：
Tandem Diabetes报告了另一个强劲增长季度，导致全年增长预测提高至17%-18%。这一表现主要归因于Mobi推出的持续成功。
尽管交出了又一个超越预期并提升未来指引的季度，这是连续的第三次，股价却经历了下跌。市场反应的原因是对未来增长驱动力强度的持续不确定性。人们认为公司已经做出了明确积极的转变，期待基础方面将逐步改善。尽管如此，仍在保持谨慎立场，需要更大的保证来支撑销售增长的持久因素。
分析师指出，Tandem Diabetes第三季度营业收入超出预期，尽管部分贡献来自于与美国供应和国际分销商订单相关的时间利益。他们观察到，在美国，第三季度的泵装出货量与他们的预测紧密相符。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
